Table 2.

Bispecific antibodies

Target	Drug	Trial, phase	Outcomes
c-Met/EGFR	Amivantamab	CHRYSALIS [68] N = 45, osimertinib-relapsed EGFRm Phase 1/1B	ORR 36% DOR 9.6 mo mPFS 4.9 mo
		MARIPOSA-2 [76] (CT vs. plus CT vs. plus lazertinib-CT) N = 263 vs. 131 vs. 263 Phase 3	CT alone vs. plus CT vs. plus Lazertinib-CT: ORR 36% vs. 64% vs. 63% DOR 5.6 vs. 6.9 vs. 9.4 mo mPFS 4.2 vs. 8.2 vs. 8.3 mo
PD-L1/VEGF	Ivonescimab (AK112)	NCT05184712 [77] (AK112 vs. CT) N = 161 vs. 161 Phase 3	AK112 vs. CT: mPFS 7.1 mo vs. 4.8 mo
HER3/EGFR	BL-B01D1	NCT05194982 [78] (EGFR-WT vs. EGFRm) N = 50 vs. 38 Phase 1 (ongoing)	EGFR-WT vs. EGFRm: ORR 44% vs. 63.2% mPFS 5.2 mo vs. 6.9 mo (immature) DCR 94% vs. 89.5%
	Izalontamab (SI-B001)	NCT05020457 [79] N = 45, SI-B001 plus doecetaxel Phase 2 (ongoing)	ORR 31.3% DCR 77.1%

ORR: overall response rate; DOR: duration of response; mPFS: median progression-free survival; DCR: disease control rate; EGFRm: EGFR-mutated; EGFR-WT: EGFR wild type; CT: chemotherapy; HER3: human epidermal growth factor receptor 3